Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed type of malignant tumor and is the second leading cause of cancer-related deaths worldwide. It is estimated that there were about 841,000 new cases and 782,000 deaths caused by liver cancer worldwide in 2018 ([@ref-3]), with Chinese patients making up more than half of the global HCC burden ([@ref-23]; [@ref-3]). The high incidence of HCC in parts of Asia is mainly due to the prevalence of hepatitis B virus and C virus infections, especially the hepatitis B virus ([@ref-3]). Accumulating evidence has shown that carcinogenesis and progression of HCC are closely related to overexpression of various oncogenes and inactivation of tumor suppressor genes.

The poor prognosis associated with HCC is attributed to the lack of effective diagnostic and therapeutic methods in the early stage of the disease. In recent years, gene targeting therapy has been increasingly used for the treatment of advanced HCC, and significant progress has been made. The most commonly reported genetic alterations in HCC include mutations in the TERT promoter, TP53, CTNB1, AXIN1, ARID1A, CDKN2A, ARID2, RPS6KA3, and CCND1 ([@ref-26]). Sorafenib targets multiple kinases and has been approved by the US Food and Drug Administration for the treatment of advanced HCC ([@ref-61]). However, sorafenib has many shortcomings, such as low efficiency, high cost, and multiple side effects ([@ref-20]). Therefore, there is an urgent need to explore the relationship between the new gene function and the occurrence, development, and malignant characteristics of HCC, as well as to elucidate the precise molecular mechanisms underlying HCC, develop early screening methods, and discover novel and effective therapeutic strategies.

Recently, high-throughput technologies and gene chips have served as rapid methods for the identification of differentially expressed genes (DEGs) and functional pathways involved in the initiation and development of various diseases ([@ref-43]; [@ref-50]). In these studies, a large number of tumor samples can be analyzed and thousands of genes can be identified; as a result, bioinformatics methods have become necessary for the analysis of gene expression profiles. However, obtaining reliable results from a single gene expression profile data is difficult, considering the potentially large number of differentially expressed genes, lack of stability and reproducibility, and high false-positive rates.

The RobustRankAggreg (RRA), which is based on a statistical model, is a biological analysis method for the integration and analysis of multiple gene lists ([@ref-27]). RRA is a rank aggregation algorithm that assumes that all genes are arranged randomly in each dataset. A gene with a higher ranking in all datasets has a lower *P*-value and has a higher likelihood of being a DEG. Compared to other strategies used for the meta-analysis of datasets from multiple databases, the RRA method is more robust and easier to compute and facilitates better evaluation of the significance of the results. In addition, the RRA algorithm can handle the variable number of genes identified from different microarray platforms. More importantly, the RRA method does not strictly require the use of certain subset of problems or complete datasets to produce highly reliable results ([@ref-27]). Therefore, the RRA algorithm is highly suitable for the integrated analysis of datasets from multiple databases.

In the present study, four GSE datasets [GSE19665](GSE19665) ([@ref-10]), [GSE55092](GSE55092) ([@ref-35]), [GSE94660](GSE94660) ([@ref-54]), and [GSE121248](GSE121248) ([@ref-52]) were downloaded from GEO; these datasets comprise a total of 299 samples, including 145 hepatitis B virus (HBV)-related HCC tissues and 154 non-cancerous tissues (chronic hepatitis B patients). The chip probe IDs were converted to their corresponding gene symbols. Bioinformatics analysis using R software and RRA method was then performed to obtain the integrated differentially expressed genes (DEGs). The Gene Ontology (GO; <http://www.geneontology.org>) is a public bioinformatics resource that provides information about gene product function using ontologies to represent biological knowledge ([@ref-15]). KEGG (Kyoto Encyclopedia of Genes and Genomes) is a knowledgebase used for the systematic analysis of gene functions and for linking genomic information with higher-order functional information ([@ref-24]). Herein, enriched GO terms and KEGG pathways were identified using the online tool DAVID 6.7. Then, the protein-protein interaction (PPI) network of the DEGs was constructed, and the hub genes were identified. We constructed the network using the hub genes and their co-expressed genes and analyzed the biological processes associated with the hub genes. Finally, survival analysis was performed based on the hub DEGs by generating the Kaplan--Meier curves in the cBioPortal. Therefore, the hub DEGs and the associated enriched pathways identified in this study can serve as reliable molecular markers for HBV-related HCC.

Material and methods
====================

Microarray data
---------------

Gene expression profiles of [GSE19665](GSE19665), [GSE55092](GSE55092), [GSE94660](GSE94660) and [GSE121248](GSE121248) were acquired from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). [GSE19665](GSE19665), [GSE55092](GSE55092) and [GSE121248](GSE121248) dataset were based on the platforms of [GPL570](GPL570) \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array, while the platform of the [GSE94660](GSE94660) dataset was [GPL16791](GPL16791) Illumina HiSeq 2500 (Homo sapiens). [GSE19665](GSE19665), [GSE55092](GSE55092), [GSE94660](GSE94660), [GSE121248](GSE121248) contain 5, 91, 21 and 37 cases of non-cancerous tissues from chronic hepatitis B patients, and 5, 49, 21 and 70 cases of HBV related HCC tissues respectively. The series matrix TXT files and platform TXT files of the four databases were downloaded separately, and the information is shown in [Table 1](#table-1){ref-type="table"}. To obtain the international standard gene name, the process of the conversion of gene probe IDs in the matrix files to the gene symbols in the platform files was performed by using A Perl language command. Subsequently, the gene expression data, normalized by the normalization Between Arrays function, was subjected to log2 transformation in the limma R package (<http://www.bioconductor.org/>) ([@ref-42]). Mean values of log~2~FC was used when multiple probe sets are used for one gene.
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###### Details of the GEO HBV-related HCC data.
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  GEO                      Sample                           Platform               Normal   Tumor   Reference
  ------------------------ -------------------------------- ---------------------- -------- ------- -----------
  [GSE19665](GSE19665)     hepatocellular carcinoma (HBV)   [GPL570](GPL570)       5        5       [@ref-10]
  [GSE55092](GSE55092)     hepatocellular carcinoma (HBV)   [GPL570](GPL570)       91       49      [@ref-35]
  [GSE94660](GSE94660)     hepatocellular carcinoma (HBV)   [GPL16791](GPL16791)   21       21      [@ref-54]
  [GSE121248](GSE121248)   hepatocellular carcinoma (HBV)   [GPL570](GPL570)       37       70      [@ref-52]

**Notes.**

GEOgene expression omnibus

Screening for DEGs
------------------

The limma R package V3.5.2 in R software was used to identify DEGs in each dataset. The DEGs were screened out according to the cut-off criterion that adjusted *P*-value \< 0.05 and ---log~2~FC--- \> 1. The RobustRankAggreg (RRA) R package (<https://cran.rstudio.com/bin/windows/contrib/3.5/RobustRankAggreg_1.1.zip>) ([@ref-27]) was used to integrated and analyzed the four gene lists which were sorted by logFC value. The lists of significantly upregulated and downregulated genes were exported and saved as Excel files respectively.

GO and KEGG pathway enrichment analyses of DEGs
-----------------------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.ncifcrf.gov>) (version 6.8) ([@ref-11]; [@ref-22]), a common online program, integrates biological data and analysis tools to provide a comprehensive set of functional annotation information of large-scale lists of genes or proteins for users to grasp biological characteristics ([@ref-21]). In order to understand the selected DEGs better, GO and KEGG pathway enrichment analysis were executed by using DAVID online tool. *P* \< 0.05 was considered statistically significant.

PPI network construction and module analysis
--------------------------------------------

As a public online tool, the Search Tool for the Retrieval of Interacting Genes (STRING) (<https://string-db.org/>) is designed to construct a critical assessment and intergration of PPI network, including direct (physical) and indirect (function) association ([@ref-48]). To know the interactional correlation of the DEGs, PPI network was established by STRING and then displayed using Cytoscape software (3.7.1) that is a public bioinformatics software platform ([@ref-45]). Furthermore, the plug-in Molecular Complex Detection (MCODE) app in Cytoscape software ([@ref-2]) was also applied to select the significant modules of hub genes from the PPI network (degree cut-off ≥ 2, node score cut-off ≥ 0.2, K-core ≥ 2, and max depth = 100). Moreover, the KEGG and GO analyses for DEGs in modules were used to investigate their potential information by using DAVID.

Hub genes selection and analysis
--------------------------------

The hub genes were selected with degrees ≥10. The cBioPortal (<http://www.cbioportal.org>) online platform ([@ref-4]; [@ref-14]) was used to analyze the network of the hub genes and their co-expression genes. The plug-in Biological Networks Gene Oncology tool (BiNGO) (version 3.0.3) ([@ref-32]) in Cytoscape software was used to construct and visualize the biological process analysis of hub genes. The UCSC Cancer Genomics Browser (<http://genome-cancer.ucsc.edu>) ([@ref-16]) was applied to construct hierarchical clustering of hub genes. The overall survival and disease-free survival of hub genes were analyzed using the Kaplan--Meier curve in the HCC datasets (TCGA, Provisional) of the cBioPortal. Comparison of expression of these genes in multiple databases were analyzed using online database Oncomine (<http://www.oncomine.org>) ([@ref-41]).

Results
=======

Identification of DEGs in HCC
-----------------------------

Four HBV-related HCC gene expression profiles were downloaded from the NCBI GEO database. Afterwards, the gene expression data was normalized and DEGs were identified with the limma R package (adjusted *P* \< 0.05 and ---log fold change (FC)--- \> 1), and the results are shown in [Fig. S1](#supp-1){ref-type="supplementary-material"}. We screened out 648, 1,043, 1,171, and 580 DEGs respectively ([Table 2](#table-2){ref-type="table"}, [Fig. 1](#fig-1){ref-type="fig"}, [Table S1](#supp-2){ref-type="supplementary-material"}). Through the integration and analysis of RRA, a total of integrated 341 DEGs were identified from the four datasets, including 117 upregulated genes and 224 downregulated genes ([Table S2](#supp-2){ref-type="supplementary-material"}). The top 20 upregulated genes and the top 20 downregulated genes were charted on a heat map, as shown in [Fig. 2](#fig-2){ref-type="fig"}.
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###### Information of DEGs screened from each dataset.
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  GEO                      Sample                           Number of DEGs   Number of upregulated genes   Number of downregulated genes
  ------------------------ -------------------------------- ---------------- ----------------------------- -------------------------------
  [GSE19665](GSE19665)     hepatocellular carcinoma (HBV)   648              257                           391
  [GSE55092](GSE55092)     hepatocellular carcinoma (HBV)   1,034            409                           634
  [GSE94660](GSE94660)     hepatocellular carcinoma (HBV)   1,171            360                           811
  [GSE121248](GSE121248)   hepatocellular carcinoma (HBV)   580              167                           413

**Notes.**

GEOgene expression omnibus

![Differential expression genes between the two groups of samples in each dataset.\
(A) [GSE19665](GSE19665), (B) [GSE55092](GSE55092), (C) [GSE94660](GSE94660), (D) [GSE121248](GSE121248). The red dots represent the upregulated genes based on an adjusted *P* \< 0.05 and log fold change \> 1; the green dots represent the downregulated genes based on an adjusted *P* \< 0.05 and log fold change \< 1; the black spots represent genes with no significant difference in expression.](peerj-07-7408-g001){#fig-1}

![Log FC Heatmap of the top 20 DEGs (upregulated genes and downregulated genes) expression in all datasets.\
The abscissa represent the GEO IDs, the ordinate represents the gene name, the red represents log FC \> 0, the white represents log FC = 0, the green represents log FC \< 0 and the value in the box represents the log FC value.](peerj-07-7408-g002){#fig-2}

Functional enrichment analyses of DEGs
--------------------------------------

To further investigate the biological functions of the 314 DEGs, GO analysis was performed using online database DAVID 6.7. As shown in [Figs. 3A](#fig-3){ref-type="fig"} and [3B](#fig-3){ref-type="fig"} and [Table 3](#table-3){ref-type="table"}, GO analysis can be divided into three functional groups: biological process group (BP), the cellular component group (CC), and the molecular function group (MF).The results of GO analysis exhibited that the integrated DEGs were particularly enriched in the BP, including cell cycle, M phase, cell cycle phase, mitosis and nuclear division for the upregulated DEGs and oxidation reduction, innate immune response, complement activation, response to wounding and activation of plasma proteins involved in acute inflammatory response for the downregulated DEGs. For the CC, the upregulated DEGs were mainly enriched in mitotic spindle, microtubule cytoskeleton, cytoskeletal part, cytoskeleton and spindle pole and the downregulated DEGs were enriched in extracellular region, extracellular region part, extracellular space, microsome, vesicular fraction. In the MF, the upregulated DEGs were principally enriched in ATP binding, adenyl ribonucleotide binding, adenyl nucleotide binding, purine nucleoside binding, nucleoside binding, and the downregulated DEGs were enriched in electron carrier activity, oxygen binding, iron ion binding, heme binding, tetrapyrrole binding.

![(A) GO analysis of upregulated DEGs. (B) GO analysis of downregulated DEGs. (C) KEGG pathway of DEGs.](peerj-07-7408-g003){#fig-3}
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###### Top 15 GO enrichment terms of differentially expressed genes associated with hepatitis B-related hepatocellular carcinoma.
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  **Expression**      **Category**                                                                       **Term**                         **Count**   **%**      ***P* value**
  ------------------- ---------------------------------------------------------------------------------- -------------------------------- ----------- ---------- ---------------
  **upregulated**     BP                                                                                 GO:0007049∼cell cycle            43          38.39286   7.63E-28
  BP                  GO:0000279∼M phase                                                                 32                               28.57143    2.48E-27   
  BP                  GO:0022403∼cell cycle phase                                                        33                               29.46429    1.59E-25   
  BP                  GO:0007067∼mitosis                                                                 27                               24.10714    2.03E-25   
  BP                  GO:0000280∼nuclear division                                                        27                               24.10714    2.03E-25   
  CC                  GO:0005819∼ mitotic spindle                                                        21                               18.75       1.43E-21   
  CC                  GO:0015630∼microtubule cytoskeleton                                                24                               21.42857    2.84E-13   
  CC                  GO:0044430∼cytoskeletal part                                                       25                               22.32143    3.19E-09   
  CC                  GO:0005856∼cytoskeleton                                                            28                               25          5.91E-08   
  CC                  GO:0000922∼spindle pole                                                            7                                6.25        6.75E-08   
  MF                  GO:0005524∼ATP binding                                                             24                               21.42857    3.45E-05   
  MF                  GO:0032559∼adenyl ribonucleotide binding                                           24                               21.42857    4.27E-05   
  MF                  GO:0030554∼adenyl nucleotide binding                                               24                               21.42857    9.64E-05   
  MF                  GO:0001883∼purine nucleoside binding                                               24                               21.42857    1.22E-04   
  MF                  GO:0001882∼nucleoside binding                                                      24                               21.42857    1.35E-04   
  **downregulated**   BP                                                                                 GO:0055114∼oxidation reduction   36          16.66667   7.03E-14
  BP                  GO:0045087∼innate immune response                                                  15                               6.944444    1.67E-09   
  BP                  GO:0006956∼complement activation                                                   10                               4.62963     1.78E-09   
  BP                  GO:0009611∼response to wounding                                                    27                               12.5        1.84E-09   
  BP                  GO:0002541∼activation of plasma proteins involved in acute inflammatory response   10                               4.62963     2.23E-09   
  CC                  GO:0005576∼extracellular region                                                    83                               38.42593    2.05E-21   
  CC                  GO:0044421∼extracellular region part                                               50                               23.14815    9.40E-16   
  CC                  GO:0005615∼extracellular space                                                     41                               18.98148    8.87E-15   
  CC                  GO:0005792∼microsome                                                               17                               7.87037     2.50E-07   
  CC                  GO:0042598∼vesicular fraction                                                      17                               7.87037     3.70E-07   
  MF                  GO:0009055∼electron carrier activity                                               23                               10.64815    1.17E-13   
  MF                  GO:0019825∼oxygen binding                                                          12                               5.555556    5.61E-12   
  MF                  GO:0005506∼iron ion binding                                                        22                               10.18519    5.88E-10   
  MF                  GO:0020037∼heme binding                                                            14                               6.481481    6.05E-09   
  MF                  GO:0046906∼tetrapyrrole binding                                                    14                               6.481481    1.33E-08   

**Notes.**

BPbiological processCCcellular componentMFmolecular functionGOgene ontology

Signaling pathway enrichment analysis
-------------------------------------

KEGG pathway enrichment analysis was performed using online database DAVID 6.7. As shown in [Fig. 3C](#fig-3){ref-type="fig"} and [Table 4](#table-4){ref-type="table"}, the results revealed that the integrated DEGs were particularly enriched in retinol metabolism, drug metabolism, metabolism of xenobiotics by cytochrome P450, caffeine metabolism and tryptophan metabolism.
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###### KEGG pathway analysis of differentially expressed genes associated with hepatitis B-related hepatocellular carcinoma.
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  **Term**                                                **Count**   **%**      ***P* value**   **Genes**
  ------------------------------------------------------- ----------- ---------- --------------- -------------------------------------------------------------------------------------------------------
  hsa00830:Retinol metabolism                             13          3.963415   3.73E-09        CYP3A4, CYP2B6, CYP2C9, CYP2C18, CYP2C8, CYP26A1, ADH1A, CYP1A2, CYP4A11, ADH4, CYP2A6, CYP2A7, RDH16
  hsa00982:Drug metabolism                                12          3.658537   2.06E-07        CYP3A4, CYP2C18, CYP2C9, CYP2B6, ADH4, CYP2C8, GSTZ1, CYP2A6, ADH1A, CYP2A7, CYP1A2, ALDH3A1
  hsa00980:Metabolism of xenobiotics by cytochrome P450   11          3.353659   1.39E-06        AKR1C3, CYP3A4, CYP2C18, CYP2C9, CYP2B6, ADH4, CYP2C8, GSTZ1, ADH1A, CYP1A2, ALDH3A1
  hsa00232:Caffeine metabolism                            5           1.52439    1.11E-05        XDH, NAT2, CYP2A6, CYP2A7, CYP1A2
  hsa00380:Tryptophan metabolism                          7           2.134146   3.62E-04        AADAT, TDO2, ACMSD, IDO2, KMO, CYP1A2, INMT
  hsa00591:Linoleic acid metabolism                       6           1.829268   4.98E-04        CYP3A4, CYP2C18, CYP2C9, AKR1B10, CYP2C8, CYP1A2
  hsa00983:Drug metabolism                                7           2.134146   5.42E-04        CYP3A4, XDH, NAT2, CDA, CYP2A6, CYP2A7, TK1
  hsa04610:Complement and coagulation cascades            8           2.439024   0.001332        C8A, C8B, C7, C9, C6, KLKB1, F9, PLG
  hsa00590:Arachidonic acid metabolism                    7           2.134146   0.002231        AKR1C3, CYP4A11, CYP2C18, CYP2C9, CYP2B6, CYP2C8, CYP4F2
  hsa04110:Cell cycle                                     10          3.04878    0.003227        CCNE2, CCNB1, CDC6, MAD2L1, BUB1B, TTK, CDC20, MCM2, PTTG1, CCNA2
  hsa00350:Tyrosine metabolism                            6           1.829268   0.004034        ADH4, GSTZ1, ADH1A, TAT, ALDH3A1, HPD
  hsa04115:p53 signaling pathway                          7           2.134146   0.005932        STEAP3, CCNE2, CCNB1, RRM2, IGF1, THBS1, IGFBP3
  hsa05020:Prion diseases                                 5           1.52439    0.009832        C8A, C8B, C7, C9, C6
  hsa00140:Steroid hormone biosynthesis                   5           1.52439    0.024978        AKR1C3, CYP3A4, HSD17B2, SRD5A2, AKR1D1
  hsa00260:Glycine, serine and threonine metabolism       4           1.219512   0.038725        SDS, AGXT2, GNMT, GLDC
  hsa04114:Oocyte meiosis                                 7           2.134146   0.05109         CCNE2, CCNB1, MAD2L1, IGF1, CDC20, AURKA, PTTG1
  hsa00010:Glycolysis/Gluconeogenesis                     5           1.52439    0.057701        ADH4, ALDOB, FBP1, ADH1A, ALDH3A1
  hsa00071:Fatty acid metabolism                          4           1.219512   0.072811        CYP4A11, ADH4, ADH1A, ACSL4
  hsa05322:Systemic lupus erythematosus                   6           1.829268   0.093168        C8A, C8B, C7, C9, C6, HIST1H4H
  hsa00360:Phenylalanine metabolism                       3           0.914634   0.099295        TAT, ALDH3A1, HPD

Integration of PPI network and module analysis
----------------------------------------------

PPI network of the 341 DEGs was established by STRING. A total of 288 DEGs (99 upregulated genes and 189 downregulated genes) were filtered into the DEG PPI network complex, which contained 288 nodes and 2,259 edges ([Fig. S2](#supp-2){ref-type="supplementary-material"}, [Tables S3](#supp-2){ref-type="supplementary-material"} and [S4](#supp-2){ref-type="supplementary-material"}). Among the 288 nodes, 59 central node genes were selected as hub genes with the criteria of filtering degree ≥ 10 (ie, each node has more than 10 connections/interactions). The top 10 hub genes were as follows: SHCBP1, FOXM1, KIF4A, ANLN, KIF15, KIF18A, FANCI, NEK2, ECT2 and RAD51AP1 ([Table 5](#table-5){ref-type="table"}).
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###### The top 10 most degree values hub genes between HBV-related HCC and normal samples.

Up indicated that the gene was identifed as up-regulated in HCC; Down indicated that the gene was reported as down-regulated. UN suggested the gene has not been reported in current HCC associated studies.
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  Gene symbol   Gene description                       logFC         Degree   Up/down
  ------------- -------------------------------------- ------------- -------- ---------
  SHCBP1        SHC binding and spindle associated 1   1.211943105   43       Up
  FOXM1         forkhead box M1                        1.832558689   43       Up
  KIF4A         kinesin family member 4A               1.850277648   43       Up
  ANLN          anillin actin binding protein          1.982343654   43       Up
  KIF15         kinesin family member 15               1.247277869   43       UN
  KIF18A        kinesin family member 18A              1.26437819    43       Up
  FANCI         FA complementation group I             1.269987824   43       UN
  NEK2          NIMA related kinase 2                  1.652396787   43       Down
  ECT2          epithelial cell transforming 2         1.418475417   43       Up
  RAD51AP1      RAD51 associated protein 1             1.585151756   42       UN

**Notes.**

FCfold change

![PPI network of module 1 (A), module 2 (B) and hierarchical clustering of hub genes was constructed using UCSC (C).\
(A and B) Circles represent genes, lines represent interactions between gene-encoded proteins and line colors represent evidence of interactions between proteins. (C) The samples under the pink bar are normal samples and the samples under the blue bar are HCC samples. Upregulation of genes is marked in red; downregulation of genes is marked in blue.](peerj-07-7408-g004){#fig-4}

Furthermore, the two most significant modules ([Figs. 4A](#fig-4){ref-type="fig"} and [4B](#fig-4){ref-type="fig"}, [Tables S5](#supp-2){ref-type="supplementary-material"} and [S6](#supp-2){ref-type="supplementary-material"}) of the PPI network were selected for KEGG pathway enrichment analysis. Results showed that the genes in module 1 were mainly enriched in cell cycle, oocyte meiosis, p53 signaling pathway, progesterone-mediated oocyte maturation, and the genes in module 2 were mainly enriched in complement and coagulation cascades, prion diseases and systemic lupus erythematosus ([Table 6](#table-6){ref-type="table"}).

Hub gene selection and analysis
-------------------------------

The biological process of the hub genes was analyzed and visualized using BiNGO in Cytoscape software and the result is shown in [Fig. 5A](#fig-5){ref-type="fig"}. The network of hub genes and their co-expression genes was constructed using cBioPortal online platform. As show in [Fig. 5B](#fig-5){ref-type="fig"}, the network contained 106 nodes, including 56 query genes and the 50 most frequently altered neighbor genes. Hierarchical cluster analysis showed that the high expression of hub genes was mainly in the region of HCC samples, whereas the low expression of hub genes was mainly in the region of non-HCC samples ([Fig. 4C](#fig-4){ref-type="fig"}). Subsequently, the prognostic information (overall survival and disease-free survival analyses) of the top 10 hub genes was available in the HCC datasets (TCGA, Provisional) of the cBioPortal online platform. HCC patients with ANLN and KIF18A alteration showed worse disease-free survival. Nonetheless, the patients with FOXM1, NEK2, RAD51AP1, ANLN, and KIF18A alteration showed worse overall survival ([Fig. 6](#fig-6){ref-type="fig"}).

Among these genes, ANLN and KIF18A showed the highest node degrees with 43. Then, HCC patients with the two genes alteration showed worse overall survival and disease-free survival. Moreover, Oncomine analysis of cancer vs. normal tissue showed that ANLN and KIF18A were highly expressed in multiple HCC datasets ([Fig. 7](#fig-7){ref-type="fig"}). These findings indicate that they may play important roles in the carcinogenesis or progression of HBV-HCC.

Discussion
==========

HCC is a common malignant tumor affecting the digestive system. The incidence of HCC in developing countries is considerably higher than that in developed countries. Chronic infection with HBV or hepatitis C virus (HCV) is the primary etiological factor related to HCC in certain parts of Asia and sub-Saharan Africa ([@ref-3]). In western countries, the main risk factors include obesity, type 2 diabetes, heavy alcohol consumption, and smoking ([@ref-12]; [@ref-36]). Although significant progress has been achieved in the diagnosis and treatment of HCC in recent years, the prognosis of HCC remains poor ([@ref-39]). Thus, there is an urgent need to understand the detailed molecular mechanisms underlying HCC for early detection, diagnosis, and treatment of the disease. Recently, the wide application of microarray and high-throughput technologies has provided an effective way to screen thousands of genes that are likely to be involved in the occurrence and development of HCC. These genes could serve as potential targets for the diagnosis and treatment of HCC.
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###### KEGG enrichment of genes in the top 2 modules.
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  Module                                             Term                                           Count      \%         *P* value                                   Genes
  -------------------------------------------------- ---------------------------------------------- ---------- ---------- ------------------------------------------- -------------------------------------------------------------------
  Modul1                                             hsa04110:Cell cycle                            10         18.18182   5.06E-11                                    CCNE2, CCNB1, CDC6, MAD2L1, BUB1B, TTK, CDC20, MCM2, PTTG1, CCNA2
  hsa04114:Oocyte meiosis                            6                                              10.90909   2.18E-05   CCNE2, CCNB1, MAD2L1, CDC20, AURKA, PTTG1   
  hsa04115:p53 signaling pathway                     3                                              5.454545   0.021056   CCNE2, CCNB1, RRM2                          
  hsa04914:Progesterone-mediated oocyte maturation   3                                              5.454545   0.032616   CCNB1, MAD2L1, CCNA2                        
  Modul2                                             hsa04610:Complement and coagulation cascades   5          45.45455   3.11E-08                                    C8A, C8B, C6, KLKB1, F9
  hsa05020:Prion diseases                            3                                              27.27273   2.74E-04   C8A, C8B, C6                                
  hsa05322:Systemic lupus erythematosus              3                                              27.27273   0.002195   C8A, C8B, C6                                

![The biological process analysis of the hub genes.\
(A) The biological process analysis of hub genes was constructed using BiNGO. The color depth of nodes refers to the corrected *P*-value of ontologies. The size of nodes refers to the numbers of genes that are involved in the ontologies. *P* \< 0.05 was considered statistically significant. (B) Hub genes and their co-expression genes were analyzed using cBioPortal. Nodes with bold black outline represent hub genes. Nodes with thin black outline represent the co-expression genes.](peerj-07-7408-g005){#fig-5}

![(A, B) Disease-free survival analyses and (C--G) overall survival of hub genes were performed using cBioPortal online platform.\
*P* \< 0.05 was considered statistically significant.](peerj-07-7408-g006){#fig-6}

![Heat maps of ANLN (A) and KIF18A (B) gene expression in multiple clinical hepatocellular carcinoma samples vs. normal tissues using Oncomine analysis.](peerj-07-7408-g007){#fig-7}

In the present study, we analyzed four mRNA expression datasets and identified a total of 341 DEGs, comprising 117 upregulated genes and 224 downregulated genes, in HBV-related HCC samples. GO and KEGG enrichment analyses showed that the upregulated genes were associated with the cell cycle (ontology: BP), mitotic spindle (ontology: CC), and adenosine triphosphate binding, adenyl ribonucleotide binding, adenyl nucleotide binding, purine nucleoside binding, and nucleoside binding (ontology: MF). The majority of the downregulated genes were enriched in oxidation reduction (ontology: BP), extracellular region (ontology: CC), and electron carrier activity (ontology: MF). The above results suggested that these DEGs are involved in the proliferation and cell cycle of chronic hepatitis B-induced HCC cells. KEGG pathway analysis revealed that the integrated DEGs were significantly enriched in retinol metabolism, drug metabolism, metabolism of xenobiotics by cytochrome P450, caffeine metabolism, and tryptophan metabolism. Previous studies have shown that dysregulation of the cell cycle and oxidation reduction play vital roles in the initiation or progression of tumors ([@ref-8]; [@ref-51]). Cytochrome P450 enzymes are involved in various types of cancer via several mechanisms, including the catalysis of the bioactivation of chemical procarcinogens, participation in the activation of cancer therapeutic drugs, as targets for cancer treatment, and as metabolic enzymes ([@ref-19]).

After screening out two modules with the most significant interactions, ten genes with the highest degrees of interaction were subsequently identified by constructing the PPI network. Results of survival analysis showed that the patients with alterations in FOXM1, NEK2, RAD51AP1, ANLN, and KIF18A expression patterns showed worse prognosis.

ANLN, an actin-binding protein, has been reported to be dysregulated in diverse human tumors ([@ref-17]). ANLN is not only considered as a proliferative marker, but also a prognostic and therapeutic indicator. ANLN knockdown was demonstrated to inhibit cell growth and migration in breast cancer ([@ref-58]). In addition, another study showed that high ANLN levels in the nuclear fraction are involved in the cell cycle and are correlated with poor prognosis ([@ref-33]). Upregulation of ANLN expression plays an important role in non-small cell lung cancers (NSCLC) by activating RHOA and participating in the phosphoinositide 3-kinase/AKT pathway ([@ref-47]). A previous study showed that ANLN expression in gastric cancer (GC) is a molecular predictor of intestinal and proliferative type gastric tumors ([@ref-40]). Furthermore, ANLN was identified as a biomarker for the prognosis of bladder urothelial carcinoma ([@ref-55]), colorectal cancer ([@ref-53]), and lung adenocarcinoma ([@ref-30]).

ANLN mRNA levels were upregulated in human HCC tissues compared to non-tumor liver tissues. ANLN knockdown was demonstrated to slow down the growth rates of tumors, reduce the number of tumors, and prolong the survival of mice ([@ref-56]). Consistent with the findings reported in previous studies ([@ref-28]), our results showed that higher ANLN expression levels are associated with worse clinical outcomes and a shorter survival times of patients with HCC, thereby highlighting the potential use of ANLN as a prognostic biomarker.

As a member of the kinesin-8 family, KIF18A plays crucial roles in regulating microtubule dynamics, chromosome congression, and cell division ([@ref-34]). In fact, elevated KIF18A expression was observed in several human cancers. KIF18A overexpression in human breast cancer has been closely associated with tumor grade, metastasis, and poor survival ([@ref-57]; [@ref-25]). Some researchers even advocate measurement of KIF18A levels in patients with estrogen receptor positive (ER+) breast cancer (BC) prior to receiving endocrine therapy ([@ref-1]). KIF18A expression levels were found to positively contribute to tumor stage, lymphatic invasion, lymph node metastasis venous invasion, and peritoneal dissemination in CRC ([@ref-37]). Proteomic analysis indicated that KIF18A is a promising biomarker for the early diagnosis of cholangiocarcinoma (CCA) ([@ref-44]).

KIF18A expression levels were found to be markedly higher in liver cancer tissues compared to adjacent normal liver tissues ([@ref-29]). KIF18A has been suggested to promote proliferation, invasion, and metastasis of HCC cells by activating cell cycle signaling pathway and the Akt and MMP-7/MMP-9-related signaling pathways ([@ref-31]). KIF18A levels were found to be significantly related to clinicopathologic factors associated with alpha-fetoprotein (AFP) concentrations (≥200 ng/mL), tumor size (≥5 cm), clinical tumor-node-metastasis (TNM) stage, and portal vein tumor thrombus (PVTT). In survival analysis, TCGA, Provisional higher KIF18A expression had worse prognosis (shorter DFS and OS) ([@ref-29]). The above results indicated that KIF18A could serve as a novel biomarker for the diagnosis and treatment of HCC. Our findings are consistent with previous studies and demonstrated that previous experiments did not show whether these HCC were associated with HBV. Therefore, the role of KIF18A in HBV-related HCC types should be verified by further experiments.

As a member of the forkhead box (Fox) transcription factor family, FOXM1 is acts as an oncogene in many tumors, such as breast, cervix, and prostate cancers, and is known to play crucial roles in the prognosis and chemoresistance of tumors ([@ref-60]). FOXM1 mRNA levels were upregulated in human HCC tissues and had positive relevance to the development, metastasis, recurrence, and worse clinical outcomes in HCC patients after orthotopic liver transplantation ([@ref-46]; [@ref-9]). SHCBP1, KIF4A, and ECT2 have been reported to mediate tumor initiation and progression of human HCC ([@ref-49]; [@ref-6]; [@ref-18]). NEK2 could serve as a useful predictor and potential therapeutic target in HCC ([@ref-13]). However, previous studies reported low NEK2 expression levels, which are inconsistent with our current findings. Other research groups reported that abnormal KIF15 levels were evidently associated with HCC progression and prognosis ([@ref-5]); however, these findings were not verified by cell or animal experiments. Similarly, these studies did not show that the occurrence of these HCCs is closely related to HBV.

FANCI and RAD51AP1 have been identified as new markers for HBV-related HCC, but have not been widely reported based on literature retrieval. Some findings provided new insights that RAD51AP1 is likely to mediate the molecular mechanisms underlying HCV-induced pathogenesis ([@ref-38]). However, further studies are required to verify the exact roles of these two genes.

In accordance with our findings, previous studies have also identified DEGs that participate in HBV-related liver cancer ([@ref-59]). For example, Zhou et al. analyzed the gene expression profiles of [GSE14520](GSE14520) and HCC samples from the Zhongshan Hospital affiliated with Fudan University, which comprised 63 paired HCC and non-tumor samples. All patients of these two cohorts were infected with hepatitis B virus. A total of 965 DEGs (389 upregulated genes and 576 downregulated genes) that were differentially regulated by at least two-fold with statistical significance. HSP90AB1, RPL8, NPM1, and MCM3 were selected as the hub genes from the PPI network. Nevertheless, the study by Zhou et al. comprised relatively fewer samples (66 primary HCC tumors and paired adjacent non-tumor tissues), and the main purpose of the study was to identify copy number variation (CNV)-driven DEGs. In another study, the DEGs that are common from four datasets were visualized using a Venn diagram ([@ref-7]). As a result, the number of DEGs obtained using this method was relatively small (84 upregulated and 46 downregulated). In the end, the following top ten hub genes were obtained: TOP2A, RFC4, CCNB1, CDC20, CDKN3, BUB1B, CCNB2, TPX2, PEN1, and MAD2L1. Compared to the previous two studies, we analyzed four GEO datasets comprising 299 samples, and 341 DEGs (117 upregulated and 224 downregulated) were identified. In addition, data analysis was conducted using the RobustRankAggreg (RRA) method, which is highly suitable for the analysis of datasets from multiple databases. Therefore, the hub genes identified in the present study are more reliable and comprehensive.

Conclusion
==========

In summary, by conducting an integrated bioinformatics analysis using multiple datasets, we identified DEGs and the association pathways involved in HBV-induced HCCs. In addition, we identified several key candidate genes and biological pathways that can provide a deeper and more comprehensive understanding of the occurrence and development of HCC and its association with HBV. Our findings provided valuable insights for the identification of novel biomarkers for the diagnosis and treatment of HCC.
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